Coloplast A/S

(PINK:CLPBY)

Latest On Coloplast A/S (CLPBY):

Date/Time Type Description Signal Details
2023-12-08 04:57 ESTDividendA dividend of $0.23 has been announced on Nov 16, 2023. It will be paid Dec 22, 2023 with an ex-dividend date of Dec 8, 2023.Neutral
2023-05-19 05:57 ESTDividendA dividend of $0.07 has been announced on May 12, 2023. It will be paid May 30, 2023 with an ex-dividend date of May 19, 2023.Neutral
2023-05-12 03:21 ESTNewsColoplast A/S (CLPBF) First Half 2022-2023 Earnings Call TranscriptN/A
2023-04-20 16:02 ESTNewsColoplast: Stock Price Is Still Decoupled From FundamentalsN/A
2023-02-03 15:22 ESTNewsColoplast A/S 2023 Q1 - Results - Earnings Call PresentationN/A
2023-02-03 15:22 ESTNewsColoplast A/S (CLPBF) Q1 2023 Earnings Call TranscriptN/A
2022-12-02 04:57 ESTDividendA dividend of $0.21 has been announced on Nov 15, 2022. It will be paid Dec 16, 2022 with an ex-dividend date of Dec 2, 2022.Neutral
2022-11-09 16:12 ESTNewsColoplast: Recession-Resilient But Still A Bit Too ExpensiveN/A
2022-11-08 04:00 ESTNewsColoplast A/S (CLPBF) Q4 2022 Earnings Call TranscriptN/A
2022-11-07 11:07 ESTNewsColoplast A/S 2022 Q4 - Results - Earnings Call PresentationN/A
2022-08-19 05:38 ESTNewsColoplast A/S' (CLPBF) CEO Kristian Villumsen on Q3 2022 Results - Earnings Call TranscriptN/A
2022-08-18 03:42 ESTNewsColoplast A/S 2022 Q2 - Results - Earnings Call PresentationN/A
2022-08-18 03:42 ESTNewsColoplast A/S 2022 Q3 - Results - Earnings Call PresentationN/A
2022-08-18 03:42 ESTNewsColoplast A/S (CLPBF) CEO Kristian Villumsen on Q3 2022 Results - Earnings Call TranscriptN/A
2022-05-13 05:58 ESTDividendA dividend of $0.07 has been announced on May 5, 2022. It will be paid May 23, 2022 with an ex-dividend date of May 13, 2022.Neutral
2022-05-09 03:19 ESTNewsColoplast A/S (CLPBF) CEO Kristian Villumsen on Q2 2022 Results - Earnings Call TranscriptN/A
2022-02-23 09:14 ESTNewsWarning: CLPBY is at high risk of cutting their dividendN/A
2022-01-27 07:23 ESTNewsColoplast A/S 2022 Q1 - Results - Earnings Call PresentationN/A
2022-01-25 22:10 ESTNewsColoplast A/S (CLPBF) CEO Kristian Villumsen on Q1 2022 Results - Earnings Call TranscriptN/A
2021-12-03 04:57 ESTDividendA dividend of $0.21 has been announced on Nov 19, 2021. It will be paid Dec 17, 2021 with an ex-dividend date of Dec 3, 2021.Neutral
2021-11-02 07:55 ESTNewsColoplast A/S's (CLPBF) CEO Kristian Villumsen on Q4 2021 Results - Earnings Call TranscriptN/A
2021-11-01 11:27 ESTNewsColoplast reports Q4 resultsN/A
2021-08-18 21:16 ESTNewsColoplast A/S 2021 Q3 - Results - Earnings Call PresentationN/A
2021-08-18 21:16 ESTNewsColoplast A/S (CLPBF) CEO Kristian Villumsen on Q3 2021 Results - Earnings Call TranscriptN/A
2021-05-14 06:02 ESTDividendA dividend of $0.08 has been announced on Nov 30, -0001. It will be paid May 24, 2021 with an ex-dividend date of May 14, 2021.Neutral
2021-03-19 06:27 ESTNewsColoplast (CLPBY) Presents At European Medtech & Services Virtual Conference - SlideshowN/A
2021-02-04 13:16 ESTFinancialsCompany financials have been released.Neutral
2021-02-02 17:40 ESTNewsColoplast A/S 2021 Q1 - Results - Earnings Call PresentationN/A
2021-02-02 17:40 ESTNewsColoplast A/S (CLPBF) CEO Kristian Villumsen on Q1 2021 Results - Earnings Call TranscriptN/A
2020-12-04 04:59 ESTDividendA dividend of $0.21 has been announced on Nov 10, 2020. It will be paid Dec 18, 2020 with an ex-dividend date of Dec 4, 2020.Neutral
2020-11-26 22:33 ESTFinancialsCompany financials have been released.Neutral
2020-11-08 01:39 ESTFinancialsCompany financials have been released.Neutral
2020-11-07 17:57 ESTFinancialsCompany financials have been released.Neutral
2020-11-07 13:24 ESTFinancialsCompany financials have been released.Neutral
2020-11-06 09:25 ESTFinancialsCompany financials have been released.Neutral
2020-11-05 09:33 ESTFinancialsCompany financials have been released.Neutral
2020-11-04 17:14 ESTNewsColoplast A/S (CLPBF) CEO Kristian Villumsen on Q4 2020 Results - Earnings Call TranscriptN/A
2020-11-03 15:16 ESTNewsColoplast A/S 2020 Q4 - Results - Earnings Call PresentationN/A
2020-11-03 15:15 ESTNewsColoplast A/S's (CLPBF) CEO Kristian Villumsen On Q4 2020 Results - Quick Version Earnings Call TranscriptN/A
2020-09-26 14:55 ESTFinancialsCompany financials have been released.Neutral
2020-09-17 06:59 ESTFinancialsCompany financials have been released.Neutral
2020-09-11 16:53 ESTNewsColoplast (CLPBY) Investor Presentation - SlideshowN/A
2020-08-31 13:59 ESTFinancialsCompany financials have been released.Neutral
2020-08-21 10:32 ESTFinancialsCompany financials have been released.Neutral
2020-08-19 00:39 ESTNewsColoplast A/S 2020 Q3 - Results - Earnings Call PresentationN/A
2020-08-19 00:39 ESTNewsColoplast A/S (CLPBF) CEO Kristian Villumsen on Q3 2020 Results - Earnings Call TranscriptN/A
2020-08-14 10:55 ESTFinancialsCompany financials have been released.Neutral
2020-08-06 10:16 ESTFinancialsCompany financials have been released.Neutral
2020-07-30 18:40 ESTFinancialsCompany financials have been released.Neutral
2020-07-30 06:38 ESTFinancialsCompany financials have been released.Neutral

About Coloplast A/S (CLPBY):

Coloplast A/S develops and markets intimate healthcare products and services worldwide. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as SpeediCath catheters that offer catheterization for both genders; Peristeen, an anal irrigation system for controlled emptying of the bowels; and Conveen Active urine bags. In addition, it provides wound care products, such as foam dressings under the Biatain brand and hydrocolloid dressing under the Comfeel brand, as well as skin care products, such as bathing and cleansing products, moisturizers, skin protectants, antifungal products, hand cleanser, and odor control products. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.

See Advanced Chart

General

  • Name Coloplast A/S
  • Symbol CLPBY
  • Type Common Stock
  • Exchange PINK
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryMedical Instruments & Supplies
  • Full Time Employees 12,500
  • Fiscal Year EndSeptember
  • Web URLhttp://www.coloplast.com
View More

Valuation

  • Trailing PE 52.33
  • Forward PE 40.65
  • Price/Sales (Trailing 12 Mt.) 10.56
  • Price/Book (Most Recent Quarter) 33.93
  • Enterprise Value Revenue 1.71
  • Enterprise Value EBITDA 4.95
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Profit Margin 23%
  • Return on Assets 26%
  • Return on Equity 76%
  • Earnings Per Share $0.28
  • Revenue Per Share $0
  • Gross Profit 12.61 billion
  • Quarterly Earnings Growth 0.6%
View More

Highlights

  • Market Capitalization 31.37 billion
  • PEG Ratio 3.99
  • Book Value Per Share $0.47
View More

Share Statistics

  • Shares Outstanding 2.13 billion
  • Shares Float 1.3 billion
  • % Held by Insiders <1%
  • % Held by Institutions 0.1%
View More

Technicals

  • Beta 0.08
  • 52 Week High $17.55
  • 52 Week Low $12.74
  • 50 Day Moving Average 15.51
  • 200 Day Moving Average 15.33
View More

Dividends

  • Forward Annual Dividend Rate $0.28
  • Forward Annual Dividend Yield 1.89%
  • Payout Ratio 12%
  • Dividend Date 2020-12-18
  • ExDividend Date 2020-12-04
  • Dividend Per Share $1.72
  • Dividend Yield 0%
View More

Coloplast A/S (CLPBY) Dividend Calendar:

CLPBY's last dividend payment was made to shareholders on December 18, 2020.
Coloplast A/S pays out 12% of its earnings out as a dividend.

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Coloplast A/S (CLPBY) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-02-02$4.74 billion$0.09
2020-09-302020-12-31$4.59 billion$0.87
2020-06-302020-09-30$4.42 billion$0.77$4.92-84.4%
2020-03-312020-06-30$4.82 billion$0.70$5.03-86%
2019-12-312020-03-31$N/A$0.74$5.01-85.25%
2019-09-302019-12-31$4.62 billion$0.77$5.49-86%
2019-06-302019-09-30$4.6 billion$0.54$5.16-89.46%
2019-03-312019-06-30$4.4 billion$0.76$4.81-84.1%
2018-12-312019-03-31$4.32 billion$0.72$4.71-84.75%
2018-09-302018-12-31$4.23 billion$0.72$5.19-86.22%
2018-06-302018-09-30$4.23 billion$0.76$4.78-84.08%
2018-03-312018-06-30$4.04 billion$0.70$4.50-84.43%
2017-12-312018-03-31$3.96 billion$0.71$4.54-84.28%
2017-09-302017-12-31$3.98 billion$0.71$4.86-85.34%
2017-06-302017-09-30$3.02 billion$0.75$4.79-84.24%
2017-03-312017-06-30$3.88 billion$0.66$4.53-85.47%
2016-12-312017-03-31$0.63$4.46-85.91%
2016-09-302016-12-31$0.63$4.76-86.74%
2016-06-302016-09-30$0.30$4.58-93.45%
2016-03-312016-06-30$0.69$4.33-84.14%
2015-12-312016-03-31$0.66$4.30-84.68%
2015-09-302015-12-31$0.56$4.21-86.62%
2015-06-302015-09-30-$1.01$3.75-126.93%
2015-03-312015-06-30$0.50$3.92-87.35%
2014-12-312015-03-31$0.55$3.96-86.13%
2014-09-302014-12-31$0.61$3.99-84.76%
2014-06-302014-09-30$0.67$3.87-82.74%
2014-03-312014-06-30$0.68$0.654.25%
2013-12-312014-03-31-$0.02$0.65-102.55%
2013-09-302013-12-31$0.67$0.00
2013-06-302013-09-30$0.63$0.00
2013-03-312013-06-30$0.58$0.00
2012-12-312013-03-31$0.51$0.00
2012-09-302012-12-31$0.51$0.00
2012-06-302012-09-30$0.49$0.00
2012-03-312012-06-30$0.47$0.00
2011-12-312012-03-31$0.43$0.00
2011-09-302011-12-31$0.40$0.00
2011-06-302011-09-30$0.45$0.00
2011-03-312011-06-30$0.44$0.00
2010-12-312011-03-31$0.35$0.00
2010-09-302010-12-31$0.34$0.00

Coloplast A/S (CLPBY) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Apr 30 2020 Mar 31 2020
Research Development 186 million 175 million 182 million 182 million 182 million
Income Before Tax 1.5 billion 1.37 billion 1.3 billion 1.3 billion 1.39 billion
Selling General Administrative 1.5 billion 1.52 billion 1.43 billion 1.43 billion 1.55 billion
Gross Profit 3.21 billion 3.16 billion 2.97 billion 2.97 billion 3.27 billion
Ebit 1.7 billion 1.59 billion 1.58 billion 1.58 billion 1.76 billion
Operating Income 1.54 billion 1.47 billion 1.37 billion 1.37 billion 1.54 billion
Income Tax Expense 359 million N/A N/A 299 million 318 million
Total Revenue 4.74 billion 4.59 billion 4.42 billion 4.42 billion 4.82 billion
Cost of Revenue 1.53 billion 1.43 billion 1.45 billion 1.45 billion 1.55 billion
Total Other Income Expense Net N/A N/A N/A N/A N/A
Net Income From Continuing Operations 1.14 billion 1.04 billion 997 million 997 million 1.07 billion
Net Income Applicable to Common Shares 1.14 billion N/A N/A 997 million 1.07 billion
Cash Flow:
Date Sep 30 2020 Jun 30 2020 Apr 30 2020 Mar 31 2020 Jan 31 2020
Investments -265 million -176 million -176 million -246 million -246 million
Change to Liabilities N/A N/A -63 million -355 million -355 million
Total Cash Flow from Investing Activities N/A N/A -176 million -246 million -246 million
Net Borrowings N/A N/A -151 million -421 million -421 million
Total Cash Flow from Financial Activities N/A N/A N/A N/A N/A
Change to Operating Activities N/A N/A 27 million -62 million -62 million
Change in Cash -74 million -90 million -90 million 11 million 11 million
Total Cash from Operating Activities 1.69 billion 1.43 billion 1.43 billion 611 million 611 million
Depreciation 215 million 214 million 214 million 214 million 214 million
Other Cash Flow from Investing Activities N/A N/A N/A N/A N/A
Change to Inventory -154 million -220 million -220 million -49 million -49 million
Change to Account Receivables N/A N/A N/A N/A N/A
Other Cash Flow from Financing Activities N/A N/A N/A N/A N/A
Change to Net Income N/A N/A 218 million 150 million 150 million
Capital Expenditures 241 million 215 million 215 million 252 million 252 million
Balance Sheet:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Apr 30 2020 Mar 31 2020
Total Liabailities 9.16 billion 6.09 billion 6.95 billion N/A 6.94 billion
Total Stockholder Equity 5.77 billion 7.41 billion 6.36 billion N/A 6.59 billion
Other Current Liabilities 3.01 billion 9 million 3 million 6.36 billion N/A
Total Assets 14.93 billion 13.5 billion 13.32 billion N/A 13.53 billion
Common Stock 216 million N/A N/A 3 million 216 million
Other Current Assets N/A N/A N/A 216 million N/A
Retained Earnings 5.88 billion 4.74 billion 6.42 billion 6.42 billion 5.6 billion
Other Liabilities 903 million N/A N/A 650 million 646 million
Other Assets 692 million N/A N/A 604 million 599 million
Cash 435 million 323 million 411 million 411 million 498 million
Total Current Liabilities 7.78 billion 4.98 billion 5.92 billion 5.92 billion 5.89 billion
Other Stockholder Equity -322 million N/A N/A -278 million -293 million
Property, Plant & Equipment 4.05 billion N/A N/A 3.8 billion 3.76 billion
Total Current Assets 6.64 billion 6.49 billion 6.49 billion 6.49 billion 6.71 billion
Long Term Investments N/A N/A N/A N/A N/A
Net Tangible Assets 2.25 billion N/A N/A 3.94 billion 4.13 billion
Short Term Investments 257 million 262 million 262 million 262 million 302 million
Long Term Debt N/A N/A N/A N/A N/A
Inventory 2.23 billion 2.23 billion 2.12 billion 2.12 billion 1.92 billion
Accounts Payable 563 million 814 million 623 million 623 million 664 million

Coloplast A/S (CLPBY) Chart:

Coloplast A/S (CLPBY) News:

Below you will find a list of latest news for Coloplast A/S (CLPBY) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Coloplast A/S (CLPBY) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

Coloplast A/S (CLPBY) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2011-08-29F-6EFRegistration of American Depository Receipt shares, immediately effectivehttps://www.sec.gov/Archives/edgar/data/1294325/000101915511000398/0001019155-11-000398-index.htm
2020-04-21F-6Registration of American Depository Receipt shares, not immediately effectivehttps://www.sec.gov/Archives/edgar/data/1294325/000101915520000072/0001019155-20-000072-index.htm
2010-11-19F-6EFRegistration of American Depository Receipt shares, immediately effectivehttps://www.sec.gov/Archives/edgar/data/1294325/000119380510002880/0001193805-10-002880-index.htm
2010-12-10F-6EFRegistration of American Depository Receipt shares, immediately effectivehttps://www.sec.gov/Archives/edgar/data/1294325/000119380510003016/0001193805-10-003016-index.htm
2015-12-09F-6EFRegistration of American Depository Receipt shares, immediately effectivehttps://www.sec.gov/Archives/edgar/data/1294325/000119380515002044/0001193805-15-002044-index.htm
2017-09-29F-6 POSPost-effective amendments for immediately effective filinghttps://www.sec.gov/Archives/edgar/data/1294325/000119380517002620/0001193805-17-002620-index.htm
2019-11-22F-6EFRegistration of American Depository Receipt shares, immediately effectivehttps://www.sec.gov/Archives/edgar/data/1294325/000119380519001750/0001193805-19-001750-index.htm
2014-11-12F-6EFRegistration of American Depository Receipt shares, immediately effectivehttps://www.sec.gov/Archives/edgar/data/1294325/000157104914006187/0001571049-14-006187-index.htm
2020-05-05EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1294325/999999999520001046/9999999995-20-001046-index.htm
2008-08-21SUPPLVoluntary Supplemental Material by Foreign Issuers [Section 11(a)]https://www.sec.gov/Archives/edgar/data/1294325/999999999708036688/9999999997-08-036688-index.htm
2008-08-12SUPPLVoluntary Supplemental Material by Foreign Issuers [Section 11(a)]https://www.sec.gov/Archives/edgar/data/1294325/999999999708037380/9999999997-08-037380-index.htm
2008-08-19SUPPLVoluntary Supplemental Material by Foreign Issuers [Section 11(a)]https://www.sec.gov/Archives/edgar/data/1294325/999999999708037396/9999999997-08-037396-index.htm
2008-09-03SUPPLVoluntary Supplemental Material by Foreign Issuers [Section 11(a)]https://www.sec.gov/Archives/edgar/data/1294325/999999999708037974/9999999997-08-037974-index.htm
2008-09-02SUPPLVoluntary Supplemental Material by Foreign Issuers [Section 11(a)]https://www.sec.gov/Archives/edgar/data/1294325/999999999708037981/9999999997-08-037981-index.htm
2008-09-15SUPPLVoluntary Supplemental Material by Foreign Issuers [Section 11(a)]https://www.sec.gov/Archives/edgar/data/1294325/999999999708039367/9999999997-08-039367-index.htm
2008-12-02SUPPLVoluntary Supplemental Material by Foreign Issuers [Section 11(a)]https://www.sec.gov/Archives/edgar/data/1294325/999999999708046711/9999999997-08-046711-index.htm
2008-12-05SUPPLVoluntary Supplemental Material by Foreign Issuers [Section 11(a)]https://www.sec.gov/Archives/edgar/data/1294325/999999999708047544/9999999997-08-047544-index.htm
2009-01-05SUPPLVoluntary Supplemental Material by Foreign Issuers [Section 11(a)]https://www.sec.gov/Archives/edgar/data/1294325/999999999709000567/9999999997-09-000567-index.htm
2009-02-03SUPPLVoluntary Supplemental Material by Foreign Issuers [Section 11(a)]https://www.sec.gov/Archives/edgar/data/1294325/999999999709003991/9999999997-09-003991-index.htm
2009-03-26SUPPLVoluntary Supplemental Material by Foreign Issuers [Section 11(a)]https://www.sec.gov/Archives/edgar/data/1294325/999999999709012262/9999999997-09-012262-index.htm
2009-04-13SUPPLVoluntary Supplemental Material by Foreign Issuers [Section 11(a)]https://www.sec.gov/Archives/edgar/data/1294325/999999999709016755/9999999997-09-016755-index.htm
2009-04-16SUPPLVoluntary Supplemental Material by Foreign Issuers [Section 11(a)]https://www.sec.gov/Archives/edgar/data/1294325/999999999709017299/9999999997-09-017299-index.htm
2009-05-04SUPPLVoluntary Supplemental Material by Foreign Issuers [Section 11(a)]https://www.sec.gov/Archives/edgar/data/1294325/999999999709019324/9999999997-09-019324-index.htm
2009-06-08SUPPLVoluntary Supplemental Material by Foreign Issuers [Section 11(a)]https://www.sec.gov/Archives/edgar/data/1294325/999999999709020788/9999999997-09-020788-index.htm
2009-09-28SUPPLVoluntary Supplemental Material by Foreign Issuers [Section 11(a)]https://www.sec.gov/Archives/edgar/data/1294325/999999999709025368/9999999997-09-025368-index.htm
2009-10-19SUPPLVoluntary Supplemental Material by Foreign Issuers [Section 11(a)]https://www.sec.gov/Archives/edgar/data/1294325/999999999709025961/9999999997-09-025961-index.htm
2009-10-28SUPPLVoluntary Supplemental Material by Foreign Issuers [Section 11(a)]https://www.sec.gov/Archives/edgar/data/1294325/999999999709026127/9999999997-09-026127-index.htm
2009-11-23ARSAnnual Report to Security Holdershttps://www.sec.gov/Archives/edgar/data/1294325/999999999709026852/9999999997-09-026852-index.htm
2009-12-17SUPPLVoluntary Supplemental Material by Foreign Issuers [Section 11(a)]https://www.sec.gov/Archives/edgar/data/1294325/999999999709027460/9999999997-09-027460-index.htm
2010-02-23SUPPLVoluntary Supplemental Material by Foreign Issuers [Section 11(a)]https://www.sec.gov/Archives/edgar/data/1294325/999999999710001213/9999999997-10-001213-index.htm
2010-04-02SUPPLVoluntary Supplemental Material by Foreign Issuers [Section 11(a)]https://www.sec.gov/Archives/edgar/data/1294325/999999999710008009/9999999997-10-008009-index.htm
2010-04-14SUPPLVoluntary Supplemental Material by Foreign Issuers [Section 11(a)]https://www.sec.gov/Archives/edgar/data/1294325/999999999710009069/9999999997-10-009069-index.htm
2010-04-22SUPPLVoluntary Supplemental Material by Foreign Issuers [Section 11(a)]https://www.sec.gov/Archives/edgar/data/1294325/999999999710009497/9999999997-10-009497-index.htm
2010-05-11SUPPLVoluntary Supplemental Material by Foreign Issuers [Section 11(a)]https://www.sec.gov/Archives/edgar/data/1294325/999999999710011052/9999999997-10-011052-index.htm
2010-06-10SUPPLVoluntary Supplemental Material by Foreign Issuers [Section 11(a)]https://www.sec.gov/Archives/edgar/data/1294325/999999999710012816/9999999997-10-012816-index.htm
2010-06-25SUPPLVoluntary Supplemental Material by Foreign Issuers [Section 11(a)]https://www.sec.gov/Archives/edgar/data/1294325/999999999710013866/9999999997-10-013866-index.htm
2010-07-19SUPPLVoluntary Supplemental Material by Foreign Issuers [Section 11(a)]https://www.sec.gov/Archives/edgar/data/1294325/999999999710015555/9999999997-10-015555-index.htm
2010-09-07SUPPLVoluntary Supplemental Material by Foreign Issuers [Section 11(a)]https://www.sec.gov/Archives/edgar/data/1294325/999999999710017790/9999999997-10-017790-index.htm
2010-09-21SUPPLVoluntary Supplemental Material by Foreign Issuers [Section 11(a)]https://www.sec.gov/Archives/edgar/data/1294325/999999999710017996/9999999997-10-017996-index.htm
2010-10-27SUPPLVoluntary Supplemental Material by Foreign Issuers [Section 11(a)]https://www.sec.gov/Archives/edgar/data/1294325/999999999710019126/9999999997-10-019126-index.htm